Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Screening for Amyloidosis Before Aortic Valve Elective Replacement

NCT04869631 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2021-02-01
Last updated
2025-02-12

Condition(s) studied

AmyloidosisAortic Valve Stenosis

Investigational drug(s) / intervention(s)

The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.

The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.: We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.

Study summary

Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).

Eligibility

Sex
ALL
Min age
40 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * age ≥40 years * written informed consent from the patient or of his/her legal guardian * hospitalization for AVR due to degenerative aortic valve stenosis Exclusion Criteria: * hemodynamically unstable patient * severe co-morbidities with an estimated life expectancy of \<1 year

Primary outcome measure(s)

  • Number/ proportion of ATTR cases identified by systematic screening — Enrolment period: 18 months

Trial sites (1)

FacilityCityRegionStatus
Charité - Universitätsmedizin Berlin Berlin Germany
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04869631 on ClinicalTrials.gov ↗ ← All trials in Germany